Breast Cancer

Hope S. Rugo, MD, from the UCSF Helen Diller Family Comprehensive Cancer Center, previews the 2012 San Antonio Breast Cancer Symposium program.

Novel combinations of hormonal therapies with targeted agents show promise for improved outcomes and are likely to become part of a new paradigm for managing patients.

Investigators have documented a significant 4.5-month median overall survival advantage with lapatinib combined with trastuzumab in women with heavily pretreated HER2-positive metastatic breast cancer.

Terry P. Mamounas, MD, MPH, from Aultman Hospital Cancer Center, discusses the administration of neoadjuvant chemotherapy for patients with early-stage breast cancer.

Six cycles of doxorubicin and cyclophosphamide or single-agent paclitaxel do not lead to a superior outcome versus four cycles as adjuvant chemotherapy in women with resected primary breast cancer.

An overview of studies looking at the potential of osteoclast inhibitors in the prevention of breast cancer recurrences in the adjuvant setting.

Sramila Aithal, MD, from Cancer Treatment Centers of America, discusses the HERceptin Adjuvant (HERA) trial that examined adjuvant therapy with trastuzumab for women with HER2-positive early breast cancer.

Massimo Cristofanilli, MD, from Fox Chase Cancer Center, discusses the investigation of small-molecule ALK inhibitors to treat patients with inflammatory breast cancer.

Pamela Munster, MD, from UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined vorinostat in combination with tamoxifen for endocrine therapy-resistant breast cancer.

A thorough examination of emerging strategies for the treatment of breast cancer, as well as the clinical data underlying new and existing options, will form the cornerstone of the 9th Annual School of Breast Oncology.

Many researchers and oncologists anticipate a role for antiangiogenic strategies in future treatment paradigms; yet just what that role will be remains elusive.

An interview with Elaine R. Mardis, PhD, discussing the clinical applications of genomic research on the near horizon that will enable more personalized therapy for patients at earlier stages of breast cancer.

Julie R. Gralow, MD, from Seattle Cancer Care Alliance, discusses the side effects associated with the administration of zoledronic acid.

Does "think pink" actually raise awareness of breast cancer?

Debu Tripathy, MD, from the USC Norris Comprehensive Cancer Center, discusses results from the phase III EMILIA trial that examined the T-DM1 for women with HER2-positive breast cancer.

Within the past two years, the oncology community has seen the FDA approve three practice-changing therapies for breast cancer and the progress of a promising fourth agent, T-DM1.

Updates on breast cancer risk factors, screening methods, and treatments for the nurse navigators who are guiding patients from diagnosis to treatment and, hopefully, through survivorship.

During the 11th International Congress on The Future of Breast Cancer, Hope Rugo, MD, offered a snapshot of the research community's progress in the study and treatment of the disease.

Combining tamoxifen with everolimus increased the clinical benefit rate, time to progression, and overall survival versus tamoxifen alone in postmenopausal women with metastatic breast cancer.

Long-term follow-up of the HERA trial confirms that 1 year of adjuvant therapy with trastuzumab should remain the standard of care for treatment of women with HER2-positive invasive early breast cancer.